| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -18,690 | -12,718 |
| Non-cash interest expense on liability related to the sales of future royalties, net of issuance costs accretion | 8,005 | 5,435 |
| Depreciation | 253 | 169 |
| Share-based compensation expense | 2,161 | 1,415 |
| Change in fair value of warrant liabilities | -5,500 | -1,927 |
| Issuance costs allocated to warrant liabilities | 0 | 0 |
| Amortization and accretion of available-for-sale investments, net | 0 | 0 |
| Prepaid expenses and other current assets | 199 | 1,155 |
| Other assets and liabilities | 36 | 25 |
| Accounts payable and accrued liabilities (includes 223 to a related party for the nine months ended september 30, 2024) | -2,033 | -1,753 |
| Deferred revenue | 0 | 0 |
| Net cash used in operating activities | -16,039 | -10,559 |
| Acquisition of property and equipment | 9 | 9 |
| Purchase of short-term investments | 0 | 0 |
| Maturity of short-term investments | 0 | - |
| Net cash used in investing activities | -9 | -9 |
| Proceeds from issuance of common stock and warrants under registered direct offering, net of issuance costs | 0 | 0 |
| Proceeds from at-the-market sales agreement, net of issuance costs | 1,411 | 1,411 |
| Proceeds from royalty purchase and sale agreement, net of issuance cost | 2,895 | - |
| Payments on royalty purchase and sale agreement | 1,500 | 1,500 |
| Proceeds from exercise of stock options | 0 | 0 |
| Proceeds from shares issued under employee stock purchase plan | 23 | 13 |
| Net cash provided by financing activities | 2,829 | -76 |
| Net decrease in cash and cash equivalents | -13,219 | -10,644 |
| Cash and cash equivalents at beginning of period | 20,020 | - |
| Cash and cash equivalents at end of period | 6,801 | - |
Clearside Biomedical, Inc. (CLSD)
Clearside Biomedical, Inc. (CLSD)